NASDAQ:SGEN - Seattle Genetics Stock Price, Forecast & News

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

Seattle Genetics, Inc. (NASDAQ:SGEN) announced its quarterly earnings results on Thursday, February, 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.60. The biotechnology company had revenue of $289.80 million for the quarter, compared to analyst estimates of $219.21 million. Seattle Genetics had a negative return on equity of 13.99% and a negative net margin of 17.31%. The company's quarterly revenue was up 66.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.75) EPS. View Seattle Genetics' Earnings History.

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Seattle Genetics.

Seattle Genetics issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $810-865 million, compared to the consensus revenue estimate of $1.1 billion.

20 analysts have issued 12 month price objectives for Seattle Genetics' shares. Their forecasts range from $95.00 to $165.00. On average, they anticipate Seattle Genetics' stock price to reach $122.12 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Price Targets for Seattle Genetics.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics.

News coverage about SGEN stock has been trending very negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Seattle Genetics earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near term. View News Stories for Seattle Genetics.

Some companies that are related to Seattle Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Seattle Genetics investors own include Immunomedics (IMMU), Gilead Sciences (GILD), Celgene (CELG), AbbVie (ABBV), NVIDIA (NVDA), Incyte (INCY), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU) and Alexion Pharmaceuticals (ALXN).

Seattle Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Capital International Investors (10.60%), Baillie Gifford & Co. (2.47%), State Street Corp (1.82%), FMR LLC (0.88%), Capital International Inc. CA (0.70%) and Capital Bank & Trust Co (0.65%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, David W Gryska, Jean I Liu, Jonathan G Drachman, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

SGEN stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Amundi Pioneer Asset Management Inc., Janus Henderson Group PLC, State Street Corp, DekaBank Deutsche Girozentrale, Mitsubishi UFJ Trust & Banking Corp, UBS Group AG and Manning & Napier Group LLC. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

SGEN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Eagle Asset Management Inc., Boxer Capital LLC, Capital International Investors, Lord Abbett & CO. LLC, Samlyn Capital LLC and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Seattle Genetics.

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SGEN stock can currently be purchased for approximately $119.97.

Seattle Genetics has a market capitalization of $20.67 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Seattle Genetics employs 1,605 workers across the globe.View Additional Information About Seattle Genetics.

The official website for Seattle Genetics is http://www.seattlegenetics.com/.

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]